For the same level of efficacy, the 300 IR tablet has been selected.
Furthermore, the onset of action was achieved from the 4th month of treatment, meaning that the difference between the placebo and the treated groups was statistically significant, the treatment effect being maintained at the same level up to the end of the study.
The quality of life has been statistically improved and the proportion of symptom-controlled days increased by 52%.
The study will be pursued over 1 year on an observational basis in accordance with protocol.
"The conduct of clinical trials in perennial allergic rhinitis is a major challenge. The outcomes of the VO57.07 are clearly good and consistent, clinically important and relevant", said Prof. Karl-Christian Bergmann, international coordinator of the study. "These results are more than promising for the roll-over of the development of house dust mites sublingual desensitization therapy".
About House Dust Mites Allergic Rhinitis
In Europe, on average, almost 40% of respiratory allergic conditions are caused by house dust mites, making this the leading cause of respiratory allergy ahead of grass pollens. From early childhood, house dust mites can trigger allergic rhinitis, worsening over time with a natural progression towards asthma. The symptoms may be severe, significantly impairing patients' quality of life.
About the Stalair(R) Development Program
According to World Health Organization (WHO) estimates, 20 to 25% of the
world's population currently suffers from respiratory allergic symptoms
(rhinoconjunctivitis, rhinitis and/or asthma). By 2020, 50% of the world
Copyright©2009 PR Newswire.
All rights reserved